novabay pharmaceuticals inc novabay pharmaceuticals inc no menu assigned           presenting a sea change in lid  lash hygiene avenova® is formulated with neutrox® novabay’s pure proprietary hypochlorous acid formulation go beyond betadine with avenova learn more about avenova novabay is a biopharmaceutical company focusing on the commercialization of prescription avenova® for the eye care market about us avenova is the essential part of any lid and lash hygiene regimen learn about our products novabay is addressing the large unmet therapeutic needs of the global antiinfective market with its pure proprietary stable form of hypochlorous acid called neutrox® information for investors top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring contact  novabay contact  novabay no menu assigned contact novabay pharmaceuticals inc  powell street suite  emeryville ca  office   fax   general inquiries corporate and investor relations inquiries thomas paulson mba chief financial officer contact tom sales and marketing inquiries glenn moro vice president sales  marketing avenova contact glenn sign up for our press releases subscribe top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring about  novabay about  novabay no menu assigned about management team board of directors ophthalmic advisory board optometry advisory board contact us going beyond antibiotics® developing antiinfective compounds effective against bacteria viruses and fungi novabay pharmaceuticals inc is a biopharmaceutical company developing products for the eye care market we are currently focused primarily on commercializing prescription avenova® for managing hygiene of the eyelids and lashes in the united states avenova is the only eye care product formulated with a proprietary stable and pure form of hypochlorous acid called neutrox® by replicating the antimicrobial chemicals used by white blood cells to fight infection neutrox has proven in laboratory testing to have broad antimicrobial properties avenova with neutrox removes debris from the skin on eyelids and lashes without burning or stinging we have developed additional commercial products containing neutrox including our neutrophase® skin and wound cleanser for wound care and cellerx® for the dermatology market we have partnerships for neutrophase in the us as well as select overseas markets most notably china in addition to our neutrox family of products we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global topical antiinfective market this second product category includes auriclosene our lead clinicalstage aganocide® compound which is a patented synthetic molecule with a broad spectrum of activity against bacteria viruses and fungi top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring press releases  novabay press releases  novabay no menu assigned news press releases published articles posters media press releases select year            date description jul    novabay pharmaceuticals announces cfo transition jun    novabay pharmaceuticals joins the russell microcap index may    novabay pharmaceuticals to present at the th annual ld micro invitational may    novabay pharmaceuticals receives noncompliance notice from nyse mkt may    novabay pharmaceuticals reports first quarter  financial results may    novabay pharmaceuticals to hold  first quarter conference call on may   mar    novabay pharmaceuticals reports  full year and fourth quarter financial results and provides  financial guidance mar    novabay pharmaceuticals to hold  fourth quarter and full year conference call on march   mar    novabay pharmaceuticals to present features and benefits of the intellicase at fda public advisory meeting mar    novabay pharmaceuticals to present at th annual roth conference jan    novabay pharmaceuticals announces preliminary sales for the fourth quarter of  nov    novabay pharmaceuticals reports  third quarter financial results nov    novabay pharmaceuticals to hold third quarter  conference call on november  oct    novabay pharmaceuticals successfully regains compliance with nyse continued listing requirements oct    novabay pharmaceuticals receives  million from early warrant exercise sep    novabay pharmaceuticals’ auriclosene® demonstrates statistically significant and clinically meaningful results in phase b study for the prevention of urinary catheter blockage and encrustation sep    novabay pharmaceuticals’ neutrox® product line receives ce mark and iso certification for the european union sep    novabay pharmaceuticals to present at the rodman  renshaw global investment conference aug    novabay pharmaceuticals reports  second quarter financial results aug    novabay pharmaceuticals to hold second quarter  conference call on august  aug    novabay pharmaceuticals completes  million private placement jun    novabay pharmaceuticals appoints mark m sieczkarek president and chief executive officer may    novabay pharmaceuticals reports  first quarter financial results may    novabay pharmaceuticals appoints todd zavodnick to its board of directors may    novabay pharmaceuticals to hold first quarter  conference call on may  may    clinical data presented at arvo showing novabay’s avenova reduces bacteria on ocular skin surface by more than  apr    novabay pharmaceuticals announces agreement for nearly  million in twotranche private placement mar    novabay pharmaceuticals announces filing of annual report on form k mar    novabay pharmaceuticals to present at th annual roth conference mar    novabay pharmaceuticals reports  fourth quarter and full year financial results feb    novabay pharmaceuticals to hold  fourth quarter and full year conference call on march  jan    novabay pharmaceuticals expects fourth quarter  avenova sales to exceed  million jan    novabay pharmaceuticals secures  million bridge loan dec    novabay declares reverse stock split nov    novabay pharmaceuticals announces restructuring to focus on avenova commercialization and reports third quarter financial results nov    novabay pharmaceuticals reschedules third quarter  conference call to november  nov    novabay pharmaceuticals reschedules third quarter  conference call to november  nov    novabay pharmaceuticals to hold third quarter  conference call on november  nov    novabay pharmaceuticals completes  patient phase b clinical study oct    novabay announces pricing of public offering of common stock and warrants oct    novabay pharmaceuticals provides update on avenova sales growth reports progress with intellicase test market launch and product pipeline advancement sep    novabay pharmaceuticals announces partnership with alphaeon to bring avenova to ophthalmologists and their patients across the us sep    novabay pharmaceuticals signs agreement with nation’s second largest independent optometry group alldocs sep    novabay pharmaceuticals to present at rodman  renshaw global investment conference sep    novabay pharmaceuticals signs distribution agreement to make avenova available in new zealand aug    novabay pharmaceuticals’ intellicase featured on abc television aug    novabay pharmaceuticals reports  second quarter financial results jul    novabay pharmaceuticals to hold second quarter  conference call on august  jul    novabay pharmaceuticals plan of compliance accepted by nyse jun    novabay pharmaceuticals conference call today june th  at  pm eastern time jun    fda clears novabay pharmaceuticals’ new hightech device intellicase for safely disinfecting contact lenses with hydrogen peroxide may    novabay announces  million “at market” private placement may    novabay pharmaceuticals reports  first quarter financial results and provides business update may    novabay pharmaceuticals to feature key opinion leaders in ophthalmology and optometry at analyst and investor day event on may  may    new laboratory study shows that novabay pharmaceuticals’ avenova completely inactivates the bacterial enzyme that contributes to blepharitis and meibomian gland dysfunction may    novabay pharmaceuticals’ avenova brings significant improvement to patients with blepharitis new study finds may    novabay pharmaceuticals receives noncompliance notice from nyse mkt apr    novabay pharmaceuticals announces the effectiveness of sec registration statement apr    novabay signs distribution agreement with amerisourcebergen corporation for avenova apr    novabay pharmaceuticals appoints mark m sieczkarek chairman apr    novabay pharmaceuticals to offer educational workshop on eye lid management at the ascrs annual symposium in san diego mar    novabay pharmaceuticals reports  fourth quarter and full year financial results and provides business update mar    novabay’s avenova featured in ophthalmology management mar    the national necrotizing fasciitis foundation names novabay’s neutrophase as its official “flesh eating disease” wound cleanser mar    novabay pharmaceuticals provides update on avenova sales growth mar    novabay pharmaceuticals signs avenova and neutrophase distribution agreements mar    novabay to present at th annual roth conference mar    novabay announces  million private placement jan    novabay signs avenova distribution agreement with cardinal health jan    novabay will expand marketing for avenova at arab health  jan    novabay management and key industry opinion leaders to hold investment community conference call today january st  at  pm et jan    novabay expands sales force for avenova jan    novabay announces new business strategy focusing on products for eye care jan    novabay rebrands its ilid cleanser as avenova dec    christmas gift to people worldwide suffering from “flesh eating” disease novabay pharmaceuticals and the national necrotizing fasciitis foundation will offer new life and limbsaving treatment at no charge to patients worldwide dec    china pioneer pharma joins hand with novabay pharmaceuticals and the nnff to offer free new lifesaving treatment for “flesheating” disease dec    novabay executive officers report insider buying of  common shares to the sec dec    novabay signs distribution agreement with the biopharm group dec    novabay’s ilid cleanser featured in review of optometry dec    novabay pharmaceuticals will attend annual ld micro conference nov    white paper describes novabay’s nonantibiotic antiinfective portfolio nov    novabay signs distribution agreement with mckesson for ilid cleanser nov    novabay pharmaceuticals reports third quarter  financial results and a clinicalbusiness update nov    novabay will discuss ilidcleanser at the academy of optometry  conference nov    novabay’s neutrophase cleared for sale by taiwan fda oct    new eye treatment is “one of the best tools i’ve found” patient reports oct    novabay pharmaceuticals receives nd major neutrophase order for  units from china pioneer pharma oct    novabay pharmaceuticals to present successful patient case histories of ilid cleanser use at the  american academy of ophthalmology meeting oct    novabay expands ilid cleanser market reach with addition to vision source network sep    novabay receives first large neutrophase order from china pioneer pharma sep    novabay pharmaceuticals creates optometry advisory board sep    novabay pharmaceuticals will feature ilid cleanser for the first time at vision expo west sep    novabay pharmaceuticals to present at rodman  renshaw th annual healthcare conference sep    center director of omni eye surgery in new york city describes a promising new product for the management of eyelid disease in news publication sep    china’s food and drug administration has cleared novabay’s neutrophase® skin and wound cleanser for sale throughout mainland china by novabay’s partner china pioneer pharma aug    novabay pharmaceuticals adds five top ophthalmologists to its ophthalmic advisory board aug    novabay pharmaceuticals deploys direct sales force to market ilid cleanser across the us aug    novabay announces results of nvc phase  for viral conjunctivitis jul    novabay pharmaceuticals reports second quarter  financial results and a clinicalbusiness update jul    in radiomd interview dr john crew describes successful new treatment for flesheating disease jul    novabay pharmaceuticals announces direct us marketingsales campaign for new ilidtm cleanser product jul    letter to novabay shareholders jul    novabay’s new product for serious eye conditions highlighted in ceolivetv interview jun    dr christine w sindt will describe benefits of novabay’s ilid cleanser at american optometric association meeting jun    ophthalmology times highlights the benefits of new ilidtm cleanser may    novabay pharmaceuticals announces presentation of positive data from its clinical trial of auriclosene irrigation solution for urinary catheter encrustation and blockage may    novabay pharmaceuticals announces completion of enrollment in its global phase b clinical trial baynovation may    novabay pharmaceuticals reports first quarter  financial results and a clinicalbusiness update apr    chronic wounds cost the nation more than  billion per year reports ron najafi ceo of novabay pharmaceuticals apr    novabay pharmaceuticals’ neutrophase is focus of dr john crew’s presentation at advanced wound care care symposium apr    novabay introduces advanced ilid™ cleanser for cleaning eyelids and skin around the eye apr    wound source reports on the role of novabay’s neutrophase® in treatment of ‘flesh eating’ bacteria mar    triple amputation from flesheating disease in the united kingdom highlights importance of novabay’s neutrophase wound cleanser mar    novabay pharmaceuticals inc announces pricing of public offering of common stock and warrants mar    novabay pharmaceuticals inc announces proposed public offering of common stock and warrants mar    novabay pharmaceuticals reports fourth quarter  and  year end financial results and provides clinicalbusiness update mar    novabay ceo comments on president obama’s ‘superbug’ budget initiative and reports by the cdc on antibiotic resistance feb    novabay pharmaceuticals grants principle business enterprises exclusive marketing and distribution rights in the us for neutrophase® an advanced wound and skin cleanser feb    novabay’s neutrophase is best in class in laboratory study of  top commercial wound cleansers feb    novabay pharmaceuticals to present at the th annual dialysis convention in atlanta feb    dr john crew gives grand rounds presentation on treating wounds with novabay’s neutrophase at eisenhower medical center feb    novabay pharmaceuticals to present at bio ceo  investor conference jan    research breakthrough for deadly flesheating disease reported in the journal cell highlights importance of neutralization of toxins associated with flesh eating bacteria jan    novabay pharmaceuticals appoints mark m sieczkarek solta medical chairman and ceo and dr massimo radaelli noventia pharma ceo to its board of directors jan    novabay pharmaceuticals provides business unit update and  outlook dec    novabay pharmaceuticals announces plan to reinitiate clinical evaluation of auriclosene for impetigo in  dec    dr ron najafi ceo of novabay pharmaceuticals urges fda to formally ban antibiotic use in food production dec    novabay pharmaceuticals gain iso  certification for the design and manufacturing of neutrophase® dec    novabay pharmaceuticals and china pioneer pharma announce expansion of partnership agreement nov    novabay pharmaceuticals announces publication of novel surgical procedure for life threatening wounds and flesh eating bacteria nov    novabay pharmaceuticals reports third quarter  financial results and a clinical business update nov    novabay pharmaceuticals provides update on phase b data of auriclosene for impetigo oct    novabay calls for new approaches to antibiotic drug development to slow the rise of resistance save lives and protect the environment sep    novabay pharmaceuticals releases video of recent analyst and investor event in new york sep    novabay pharmaceuticals announces positive results from phase  clinical study of auriclosene to reduce urinary catheter blockage and encrustation aug    novabay ceo updates product pipeline in video interview aug    novabay pharmaceuticals reports second quarter  financial results and a clinicalbusiness update jul    novabay pharmaceuticals to present at southern california investor conference jul    novabay pharmaceuticals to present at jmp securities th annual healthcare conference jul    novabay executive interviewed on ceolive tv jun    novabay supports legislation to attack antibiotic resistance jun    novabay pharmaceuticals midyear clinical update may    novabay pharmaceuticals and virbac enter into a collaboration and license agreement for animal health may    novabay pharmaceuticals reports first quarter financial results and clinical and business update apr    novabay global ophthalmology study enrolls first patients in brazil mar    novabay ceo interviewed on redchip money report on fox business news mar    novabay pharmaceuticals reports fourth quarter financial results and  clinical and business update mar    novabay pharmaceuticals to present at the th annual roth conference mar    novabay names keith bley as senior vice president of product development feb    novabay receives unique globally recognized international nonproprietary name auriclosene for nvc feb    novabay partner galderma expands phase b trial enrollment to south africa jan    novabay pharmaceuticals to present at the th annual bio ceo  investor conference jan    novabay pharmaceuticals announces smartphone investor app jan    novabay expands global ophthalmology study of pink eye to india dec    novabay pharmaceuticals to present at biotech showcase  dec    novabay pharmaceuticals provides business update and  outlook dec    novabay pharmaceuticals inc announces pricing of public offering of common stock and warrants dec    novabay pharmaceuticals inc announces proposed public offering of common stock and warrants nov    novabay pharmaceuticals to present at lazard capital markets th annual healthcare conference nov    novabay pharmaceuticals provides third quarter  financial results sep    novabay pharmaceuticals nby receives  million from partner galderma sep    galderma and novabay enroll first patients in phase b clinical study of nvc for impetigo sep    novabay pharmaceuticals nby announces expansion of strategic marketing agreement for neutrophase in southeast asia sep    novabays neutrophase used in new therapeutic technique for management of necrotizing fasciitis sep    novabay pharmaceuticals coauthors novel study demonstrating chemical impact of nchlorotaurine and nvc on bacterial toxins sep    novabay pharmaceuticals to present at rodman  renshaw th annual healthcare conference aug    novabay pharmaceuticals receives additional fda k clearance for neutrophase wound cleanser aug    novabay pharmaceuticals to present at southern california investor conference aug    novabay pharmaceuticals provides second quarter  financial results jul    novabay pharmaceuticals to present at jmp securities healthcare conference jun    novabay announces successful endofphase a fda meeting for dermatology program may    novabay pharmaceuticals strengthens global aganocide patent estate with seven new patents may    novabay enrolls first patients in global baynovation phase b study for adenoviral conjunctivitis may    novabay’s aganocide outperformed traditional antibiotics in drug resistance study apr    novabay’s neutrophaser supports healing of chronic wounds new patient case studies highlighted at the  spring symposium on advanced wound care apr    novabay to present new case studies on neutrophaser at the  spring symposium on advanced wound care apr    novabay pharmaceuticals launches ceo blog mar    novabay pharmaceuticals provides fourth quarter and full year  financial results mar    novabay pharmaceuticals signs option agreement with virbac animal health for aganocide compounds mar    novabay pharmaceuticals to present at two upcoming investor conferences in march feb    novabay issues statement regarding market activity feb    novabay pharmaceuticals provides business update and  outlook feb    novabay pharmaceuticals to present at the th annual bio ceo  investor conference feb    novabay pharmaceuticals to hold conference call to provide yearend business update and  outlook jan    novabay prepares to launch global phase b ophthalmic study of nvc jan    novabay pharmaceuticals announces strategic marketing agreement for neutrophase in china nov    novabay establishes primary proof of concept for nvc phase  ucbe clinical program nov    novabay pharmaceuticals’ aganocide compound nvc featured in drugs of the future nov    novabay pharmaceuticals reports third quarter financial results oct    novabay pharmaceuticals names david w stroman phd as head of ophthalmic drug development sep    novabay pharmaceuticals names russell a hoon as vice president of its advanced wound care business unit sep    novabay pharmaceuticals to present at the ld micro invitational conference sep    novabay pharmaceuticals reports positive results in sinus infection study aug    novabay pharmaceuticals highlighted in cataract  refractive surgery today aug    novabay pharmaceuticals to present at the  southern california investor conference aug    novabay pharmaceuticals reports second quarter financial results jul    novabay pharmaceuticals announces the closing of its  million registered direct offering of common stock and warrants jun    novabay pharmaceuticals inc announces pricing of a  million registered direct offering of common stock and warrants jun    novabay regains worldwide rights to its aganocide compounds from alcon may    novabay pharmaceuticals to present at the th annual spring growth stock conference hosted by security research associates inc on may  may    archive of conference call re results from phase  clinical study for the treatment of adenoviral conjunctivitis may    novabay pharmaceuticals reports results from phase  clinical trial of nvc for adenoviral conjunctivitis may    novabay pharmaceuticals inc reports first quarter financial results may    novabay pharmaceuticals spotlights three new aganocide compounds with confirmed activity against ophthalmic pathogens apr    novabay pharmaceuticals spotlights positive results from neutrophase study of  patients with chronic nonhealing wounds apr    novabay pharmaceuticals awarded st place for outstanding scientific presentation at the simon foundation for continence conference apr    novabay pharmaceuticals spotlights positive results for its novel antiinfective at  simon foundation for continence conference mar    novabay pharmaceuticals releases ceo webcast on business and clinical developments from its four business units mar    novabay pharmaceuticals provides fourth quarter and full year  financial results and business unit updates mar    novabay pharmaceuticals to present at the roth capital rd annual growth stock conference on march  mar    novabay pharmaceuticals initiates phase  clinical trial for the treatment of urinary catheter blockage and encrustation feb    novabay pharmaceuticals ranked no  in biotech industry in fast company’s annual list of world’s most innovative companies feb    novabay pharmaceuticals to present at the th annual bio ceo  investor conference feb    novabay pharmaceuticals provides summary of  accomplishments and  outlook jan    novabay pharmaceuticals to present at  biotech showcase conference jan    novabay pharmaceuticals reports activity of aganocide nvc against deadly “superbug” producing ndm new delhi metallobetalactamase dec    novabay pharmaceuticals ceo contributes article to the scientist dec    novabay pharmaceuticals and galderma expand their agreement to include impetigo dec    novabay pharmaceuticals to present at the rd annual ld micro conference nov    novabay pharmaceuticals holds successful fda meeting on clinical development of aganocide® compound nvc for impetigo nov    novabay pharmaceuticals inc reports third quarter financial results nov    novabay pharmaceuticals awarded cash grant under the us government qualifying therapeutic discovery program nov    novabay pharmaceuticals to present at two upcoming investor conferences in november oct    novabay pharmaceutical’s nvc demonstrates up to  efficacy in  patient impetigo phase  clinical trial including  efficacy in mrsa infected patients oct    novabay pharmaceuticals reports on status of phase  proof of concept clinical trial of novabay’s nvc for viral conjunctivitis oct    novabay pharmaceuticals to present human clinical data on lead antiinfective compound at the th annual idsa meeting oct    novabay pharmaceuticals appoints gail maderis baybio president and ceo and former genzyme senior executive to its board of directors sep    novabay pharmaceuticals spotlights positive results for new class of antiinfectives at th annual icaac meeting aug    novabay pharmaceuticals announces resignation of board member aug    novabay pharmaceuticals inc reports second quarter financial results jul    novabay’s nonantibiotic antiinfective shows efficacy in impetigo trial jul    novabay pharmaceuticals’ nonantibiotic antiinfective successful in phase  skin infection trial jul    novabay pharmaceuticals receives notice of allowance on antiinfective nvc and related compounds may    novabay pharmaceuticals inc reports first quarter financial results may    positive data on new class of antiinfectives announced by novabay pharmaceuticals at arvo  apr    novabay pharmaceuticals announces new data on firstinclass antiinfective compounds at arvo annual meeting apr    novabay pharmaceuticals to present at bio  international convention apr    novabay pharmaceuticals reports positive data from exploratory phase  trial mar    novabay pharmaceuticals inc reports fourth quarter and full year  financial results feb    novabay pharmaceuticals to present at the  bio ceo  investor conference jan    novabay pharmaceuticals earns  million in milestone payments from galderma sa jan    novabay pharmaceuticals to present at the annual onemedplace finance forum dec    novabay pharmaceuticals to receive increase in funding and support from alcon nov    novabay pharmaceuticals reports third quarter  financial results provides pipeline update oct    novabay’s aganocides show penetration and efficacy in a preclinical infected human nail model of onychomycosis oct    novabay to hold conference call to review aganocide data presented at the infectious diseases society of america meeting oct    novabay pharmaceuticals to present at th annual bio investor forum  in san francisco oct    novabay pharmaceuticals expands management team names mark anderson phd as chief scientific officer sep    novabay pharmaceuticals to present at maxim group growth conference presentation to be webcast on september   sep    novabay pharmaceuticals is recognized as a new california  business innovator by golden capital network  hamilton lane sep    novabay presents data confirming its aganocide compounds are effective in killing bacteria that have developed multidrugresistance sep    novabay launches clinical study for nonantibiotic treatment of impetigo one of the most common skin infections sep    novabay pharmaceuticals to present at rodman  renshaw th annual healthcare conference september   in new york city aug    novabay pharmaceuticals announces the closing of its  million registered direct offering of common stock and warrants aug    novabay pharmaceuticals to present new preclinical data on lead antiinfective compound for use in onychomycosis at the  idsa annual meeting aug    novabay pharmaceuticals announces pricing of registered direct offering of common stock and warrants aug    novabay pharmaceuticals to present new data on lead antiinfective compound at the  icaac annual meeting aug    novabay pharmaceuticals names roy j wu as senior vice president for business development jul    novabay pharmaceuticals to present at jesup  lamont  growth stock conference jul    alcon commences phase  clinical trial of novabay’s nvc for viral conjunctivitis may    novabay pharmaceuticals reports first quarter  financial results apr    novabay pharmaceuticals enters into agreement to broaden intellectual property estate and expand clinical opportunities for its aganocide compounds apr    novabay pharmaceuticals appoints professor john a soderquist phd to its scientific advisory board apr    novabay pharmaceuticals announces fourth quarter and full year  financial results mar    novabay pharmaceuticals and galderma enter into global agreement to develop and commercialize novabay’s novel aganocide drugs for major dermatological conditions mar    novabay pharmaceuticals scientific advisor receives american chemical society’s highest award mar    novabay pharmaceuticals announces lead antiinfective product candidate nvc shown to be effective in treating topical fungal infection mar    novabay pharmaceuticals announces new preclinical data to be presented at the american academy of dermatology aad  annual meeting feb    novabay pharmaceuticals receives broadcast and print media coverage feb    novabay pharmaceuticals ceo dr ron najafi to present at the th annual bio ceo  investor conference jan    novabay pharmaceuticals appoints harry f hixson jr phd former amgen presidentchief operating officer to its board of directors jan    novabay’s nvc cleared by fda for human clinical trials in ophthalmology jan    novabay pharmaceuticals issued key composition of matter patent for aganocide compounds jan    novabay pharmaceuticals announces retirement of senior executive dec    novabay pharmaceuticals plans to consolidate its stock listing on the american stock exchange amex nov    patient enrollment begins in exploratory phase ii trial of novabay’s lead aganocide compound nvc in cathererassociated urinary tract infections nov    novabay pharmaceuticals reports third quarter  financial results nov    novabay pharmaceuticals to present at the th annual rodman  renshaw healthcare conference oct    what the world needs now safe nonantibiotic antiinfectives oct    the future of antimicrobials is here oct    novabay pharmaceuticals to present data on lead antiinfective compound at firstever icaacidsa joint meeting oct    novabay pharmaceuticals to present at the maxim group annual growth conference aug    novabay to present at th annual summer technology conference aug    novabay pharmaceuticals reports second quarter  financial results aug    novabay pharmaceuticals featured on kgotv san francisco jul    novabay pharmaceuticals ceo dr ron najafi joins distinguished leaders selected for this year’s pharmavoice  most influential leaders jul    novabay begins media education initiative to promote new approaches to treating “super bugs” jul    novabay announces advancements in dermatology program jun    novabay pharmaceuticals to present at the bio international convention may    novabay announces positive results from phase iia study of aganase for nasal decolonization of staph including mrsa may    novabay pharmaceuticals reports first quarter  results may    novabay’s lead aganocide compound nvc well tolerated in the bladder in phase i trial mar    novabay pharmaceuticals publishes on the design of new class of antimicrobial compounds it named aganocides mar    novabay pharmaceuticals reports fourth quarter and year end  results provides corporate highlights mar    novabay pharmaceuticals commences phase i human clinical trial for the prevention of catheter associated urinary tract infections mar    novabay pharmaceuticals inc announces year end  earnings conference call feb    novabay pharmaceuticals presentation at the th annual roth capital oc growth stock conference featured on msn money feb    novabay pharmaceuticals receives allowance of patent covering neutrophase® product feb    novabay pharmaceuticals to present at two upcoming healthcare conferences feb    novabay informs investors of inaccuracies on yahoo finance jan    novabay pharmaceuticals rang opening bell at the american stock exchange jan    novabay pharmaceutical’s investigational new drug application ind for the prevention of catheter associated urinary tract infections cleared by fda jan    novabay pharmaceuticals appoints thomas j paulson chief financial officer dec    novabay pharmaceuticals to present at the new york society of security analysts biotechspecialty pharma conference nov    novabay pharmaceuticals announces positive phase  study results with lead aganocide compound nov    novabay pharmaceuticals featured in novemberdecember issue of pharmavoice nov    novabay pharmaceuticals retains the investor relations group of new york nov    novabay pharmaceuticals announces third quarter  financial results oct    novabay pharmaceuticals closes initial public offering of common stock top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring corporate presentation  novabay corporate presentation  novabay no menu assigned investors events corporate governance corporate presentation composition of board committees sec filings stock information corporate presentation year title document july  novabay pharmaceuticals inc corporate presentation top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring neutrox  novabay neutrox  novabay no menu assigned technology neutrox aganocides neutrox® neutrox — a pure form of hypochlorous acid hocl produced by novabay’s proprietary and patented manufacturing process neutroxcontaining products have been cleared by the food  drug administration to clean skin and wounds labs tests show that neutrox identical to a naturally occurring substance produced by white blood cells as a first line of defense against microbial invaders has potent antimicrobial activity yet is nontoxic to mammalian cells moreover neutrox also neutralizes bacterial toxins and breaks up biofilms neutrox as a preservative in solution demonstrates broad spectrum antimicrobial activity antiinflammatory activity blocking both inflammatory toxins from pathogens and the body’s inflammatory mediators  in vitro testing explore our neutrox products top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring products  novabay products  novabay no menu assigned products avenova neutrophase cellerx going beyond antibiotics® novabay is proud to offer a specialized portfolio of innovative nonantibiotic antiinfective products our commitment to patients within wound care ophthalmology and dermatology is demonstrated by the brands below all of which contain novabay’s patented technology neutrox® daily lid  lash hygiene explore skin and wound cleanser explore cosmetic procedures explore top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring novabay pharmaceuticals  wikipedia novabay pharmaceuticals from wikipedia the free encyclopedia   redirected from novabay pharmaceuticals inc jump to navigation search this article needs additional citations for verification please help improve this article by adding citations to reliable sources unsourced material may be challenged and removed june  learn how and when to remove this template message novabay pharmaceuticalsinc fighting superbugs type public traded as nyse mkt nby founded  founder ron najafi key people mark sieczkarek mba chairman  interim ceo tom paulson mba cfo glenn morovp sales and marketing avenova justin m hall esq senior vice president general counsel website novabaycom novabay pharmaceuticals inc is an emeryville california based clinicalstage biopharmaceutical company focused on developing novel fastacting synthetic antiinfectives compounds these compounds are designed to mimic the bodys defense system against infection the company is currently focused on products for the eye care market major products include avenova cleared by fda for lid and lash cleansing as part of a regimen for blepharitis and neutrophase used in treatment of necrotizing fasciitis contents  history  corporate governance  products  products on the market  products under development  references  external links historyedit novabay pharmaceuticals inc was founded by ron najafi an organic chemist who had previously worked for several pharmaceutical chemical and biotech companies in the us najafi became intrigued by hocl hypochlorous acid an antimicrobial substance produced by white blood cells while investigating the chemical reaction of white blood cells during oxidative burst cycle hocl and other chlorinecontaining chemicals fight invading microbes these natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses rendering them inactive najafi started novabay pharmaceuticals in  to create a stable version of hoclcitation needed najafi chemistry nobel laureate herbert c brown and purdue university professor dale margerum recruited dr lu wang to novabay where she is now director of product development she was able to develop the stable version of pure hypochlorous acid without bleach impurities which became novabay’s first product neutrophasehypochlorous acid as a potential wound care agent part ii pdf  neutrophase® in chronic nonhealing wounds pdf  treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam not in citation given and cleared by the food and drug administration in  the product successfully treats a variety of chronic nonhealing wounds without the use of standard antibiotics novabay announced two new products named cellerx™ for plastic surgery and ilid™ cleanser now avenova that was cleared by fda for lid and lash cleansing as part of a regimen for blepharitis novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients  corporate governanceedit as of april  update the members of the board of directors of novabay pharmaceuticals were paul e freiman xinzhou li paul li gail maderis t alex mcpherson md phd massimo radaelli phd mark sieczkarek mijia wu bob wu and xiaoyan liu henry liu productsedit products on the marketedit avenova formerly known as ilid cleanser  neutrophase  cellerx for plastic surgery products under developmentedit novabay developed a method for making a stable pure form of hypochlorous acid hocl a substance produced by the immune system as an effective first defense against microbial invaders the company calls their proprietary formulation neutrox the companys chemists also created a related family of compounds which the company calls aganocides the company is currently developing compounds with antibacterial and antiviral action potential applications include flesheating disease problems related to indwelling urinary catheters and common eye conditions compounds are also being developed for the veterinary market referencesedit  novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients   treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam   nnff names novabays nby neutrophase its official flesheating disease wound cleanser   hypochlorous acid as a potential wound care agent part i pdf   k summary neutrophase® skin and wound cleaner otc pdf   novabay’s new advanced ilid cleanser has been cleared by the fda for cleaning removing debris and microbes from the skin around the eyes the eyelids and eyelashes eyelid and lash cleansing as part of a regimen for blepharitis  steven e f brown february   novabay pharmaceuticals makes deal for flesheating bacteria cleanser san francisco business times retrieved june     novabay pharmaceuticals and virbac enter into a collaboration and license agreement for animal health  external linksedit companies portal wwwnovabaycom wwwavenovacom wwwdoctorsavenovacom wwwneutrophasecom wwwcellerxcom novabay pharmaceuticals inc the new york times v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlenovabaypharmaceuticalsoldid categories companies listed on nyse mktpharmaceutical companies of the united statescompanies based in emeryville californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories articles needing additional references from june all articles needing additional referencespages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from june all articles with failed verificationarticles with failed verification from june articles containing potentially dated statements from april all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view novabay pharmaceuticals  wikipedia novabay pharmaceuticals from wikipedia the free encyclopedia   redirected from novabay pharmaceuticals inc jump to navigation search this article needs additional citations for verification please help improve this article by adding citations to reliable sources unsourced material may be challenged and removed june  learn how and when to remove this template message novabay pharmaceuticalsinc fighting superbugs type public traded as nyse mkt nby founded  founder ron najafi key people mark sieczkarek mba chairman  interim ceo tom paulson mba cfo glenn morovp sales and marketing avenova justin m hall esq senior vice president general counsel website novabaycom novabay pharmaceuticals inc is an emeryville california based clinicalstage biopharmaceutical company focused on developing novel fastacting synthetic antiinfectives compounds these compounds are designed to mimic the bodys defense system against infection the company is currently focused on products for the eye care market major products include avenova cleared by fda for lid and lash cleansing as part of a regimen for blepharitis and neutrophase used in treatment of necrotizing fasciitis contents  history  corporate governance  products  products on the market  products under development  references  external links historyedit novabay pharmaceuticals inc was founded by ron najafi an organic chemist who had previously worked for several pharmaceutical chemical and biotech companies in the us najafi became intrigued by hocl hypochlorous acid an antimicrobial substance produced by white blood cells while investigating the chemical reaction of white blood cells during oxidative burst cycle hocl and other chlorinecontaining chemicals fight invading microbes these natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses rendering them inactive najafi started novabay pharmaceuticals in  to create a stable version of hoclcitation needed najafi chemistry nobel laureate herbert c brown and purdue university professor dale margerum recruited dr lu wang to novabay where she is now director of product development she was able to develop the stable version of pure hypochlorous acid without bleach impurities which became novabay’s first product neutrophasehypochlorous acid as a potential wound care agent part ii pdf  neutrophase® in chronic nonhealing wounds pdf  treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam not in citation given and cleared by the food and drug administration in  the product successfully treats a variety of chronic nonhealing wounds without the use of standard antibiotics novabay announced two new products named cellerx™ for plastic surgery and ilid™ cleanser now avenova that was cleared by fda for lid and lash cleansing as part of a regimen for blepharitis novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients  corporate governanceedit as of april  update the members of the board of directors of novabay pharmaceuticals were paul e freiman xinzhou li paul li gail maderis t alex mcpherson md phd massimo radaelli phd mark sieczkarek mijia wu bob wu and xiaoyan liu henry liu productsedit products on the marketedit avenova formerly known as ilid cleanser  neutrophase  cellerx for plastic surgery products under developmentedit novabay developed a method for making a stable pure form of hypochlorous acid hocl a substance produced by the immune system as an effective first defense against microbial invaders the company calls their proprietary formulation neutrox the companys chemists also created a related family of compounds which the company calls aganocides the company is currently developing compounds with antibacterial and antiviral action potential applications include flesheating disease problems related to indwelling urinary catheters and common eye conditions compounds are also being developed for the veterinary market referencesedit  novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients   treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam   nnff names novabays nby neutrophase its official flesheating disease wound cleanser   hypochlorous acid as a potential wound care agent part i pdf   k summary neutrophase® skin and wound cleaner otc pdf   novabay’s new advanced ilid cleanser has been cleared by the fda for cleaning removing debris and microbes from the skin around the eyes the eyelids and eyelashes eyelid and lash cleansing as part of a regimen for blepharitis  steven e f brown february   novabay pharmaceuticals makes deal for flesheating bacteria cleanser san francisco business times retrieved june     novabay pharmaceuticals and virbac enter into a collaboration and license agreement for animal health  external linksedit companies portal wwwnovabaycom wwwavenovacom wwwdoctorsavenovacom wwwneutrophasecom wwwcellerxcom novabay pharmaceuticals inc the new york times v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlenovabaypharmaceuticalsoldid categories companies listed on nyse mktpharmaceutical companies of the united statescompanies based in emeryville californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories articles needing additional references from june all articles needing additional referencespages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from june all articles with failed verificationarticles with failed verification from june articles containing potentially dated statements from april all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view novabay pharmaceuticals  wikipedia novabay pharmaceuticals from wikipedia the free encyclopedia   redirected from novabay pharmaceuticals inc jump to navigation search this article needs additional citations for verification please help improve this article by adding citations to reliable sources unsourced material may be challenged and removed june  learn how and when to remove this template message novabay pharmaceuticalsinc fighting superbugs type public traded as nyse mkt nby founded  founder ron najafi key people mark sieczkarek mba chairman  interim ceo tom paulson mba cfo glenn morovp sales and marketing avenova justin m hall esq senior vice president general counsel website novabaycom novabay pharmaceuticals inc is an emeryville california based clinicalstage biopharmaceutical company focused on developing novel fastacting synthetic antiinfectives compounds these compounds are designed to mimic the bodys defense system against infection the company is currently focused on products for the eye care market major products include avenova cleared by fda for lid and lash cleansing as part of a regimen for blepharitis and neutrophase used in treatment of necrotizing fasciitis contents  history  corporate governance  products  products on the market  products under development  references  external links historyedit novabay pharmaceuticals inc was founded by ron najafi an organic chemist who had previously worked for several pharmaceutical chemical and biotech companies in the us najafi became intrigued by hocl hypochlorous acid an antimicrobial substance produced by white blood cells while investigating the chemical reaction of white blood cells during oxidative burst cycle hocl and other chlorinecontaining chemicals fight invading microbes these natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses rendering them inactive najafi started novabay pharmaceuticals in  to create a stable version of hoclcitation needed najafi chemistry nobel laureate herbert c brown and purdue university professor dale margerum recruited dr lu wang to novabay where she is now director of product development she was able to develop the stable version of pure hypochlorous acid without bleach impurities which became novabay’s first product neutrophasehypochlorous acid as a potential wound care agent part ii pdf  neutrophase® in chronic nonhealing wounds pdf  treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam not in citation given and cleared by the food and drug administration in  the product successfully treats a variety of chronic nonhealing wounds without the use of standard antibiotics novabay announced two new products named cellerx™ for plastic surgery and ilid™ cleanser now avenova that was cleared by fda for lid and lash cleansing as part of a regimen for blepharitis novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients  corporate governanceedit as of april  update the members of the board of directors of novabay pharmaceuticals were paul e freiman xinzhou li paul li gail maderis t alex mcpherson md phd massimo radaelli phd mark sieczkarek mijia wu bob wu and xiaoyan liu henry liu productsedit products on the marketedit avenova formerly known as ilid cleanser  neutrophase  cellerx for plastic surgery products under developmentedit novabay developed a method for making a stable pure form of hypochlorous acid hocl a substance produced by the immune system as an effective first defense against microbial invaders the company calls their proprietary formulation neutrox the companys chemists also created a related family of compounds which the company calls aganocides the company is currently developing compounds with antibacterial and antiviral action potential applications include flesheating disease problems related to indwelling urinary catheters and common eye conditions compounds are also being developed for the veterinary market referencesedit  novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients   treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam   nnff names novabays nby neutrophase its official flesheating disease wound cleanser   hypochlorous acid as a potential wound care agent part i pdf   k summary neutrophase® skin and wound cleaner otc pdf   novabay’s new advanced ilid cleanser has been cleared by the fda for cleaning removing debris and microbes from the skin around the eyes the eyelids and eyelashes eyelid and lash cleansing as part of a regimen for blepharitis  steven e f brown february   novabay pharmaceuticals makes deal for flesheating bacteria cleanser san francisco business times retrieved june     novabay pharmaceuticals and virbac enter into a collaboration and license agreement for animal health  external linksedit companies portal wwwnovabaycom wwwavenovacom wwwdoctorsavenovacom wwwneutrophasecom wwwcellerxcom novabay pharmaceuticals inc the new york times v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlenovabaypharmaceuticalsoldid categories companies listed on nyse mktpharmaceutical companies of the united statescompanies based in emeryville californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories articles needing additional references from june all articles needing additional referencespages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from june all articles with failed verificationarticles with failed verification from june articles containing potentially dated statements from april all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view novabay pharmaceuticals  wikipedia novabay pharmaceuticals from wikipedia the free encyclopedia   redirected from novabay pharmaceuticals inc jump to navigation search this article needs additional citations for verification please help improve this article by adding citations to reliable sources unsourced material may be challenged and removed june  learn how and when to remove this template message novabay pharmaceuticalsinc fighting superbugs type public traded as nyse mkt nby founded  founder ron najafi key people mark sieczkarek mba chairman  interim ceo tom paulson mba cfo glenn morovp sales and marketing avenova justin m hall esq senior vice president general counsel website novabaycom novabay pharmaceuticals inc is an emeryville california based clinicalstage biopharmaceutical company focused on developing novel fastacting synthetic antiinfectives compounds these compounds are designed to mimic the bodys defense system against infection the company is currently focused on products for the eye care market major products include avenova cleared by fda for lid and lash cleansing as part of a regimen for blepharitis and neutrophase used in treatment of necrotizing fasciitis contents  history  corporate governance  products  products on the market  products under development  references  external links historyedit novabay pharmaceuticals inc was founded by ron najafi an organic chemist who had previously worked for several pharmaceutical chemical and biotech companies in the us najafi became intrigued by hocl hypochlorous acid an antimicrobial substance produced by white blood cells while investigating the chemical reaction of white blood cells during oxidative burst cycle hocl and other chlorinecontaining chemicals fight invading microbes these natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses rendering them inactive najafi started novabay pharmaceuticals in  to create a stable version of hoclcitation needed najafi chemistry nobel laureate herbert c brown and purdue university professor dale margerum recruited dr lu wang to novabay where she is now director of product development she was able to develop the stable version of pure hypochlorous acid without bleach impurities which became novabay’s first product neutrophasehypochlorous acid as a potential wound care agent part ii pdf  neutrophase® in chronic nonhealing wounds pdf  treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam not in citation given and cleared by the food and drug administration in  the product successfully treats a variety of chronic nonhealing wounds without the use of standard antibiotics novabay announced two new products named cellerx™ for plastic surgery and ilid™ cleanser now avenova that was cleared by fda for lid and lash cleansing as part of a regimen for blepharitis novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients  corporate governanceedit as of april  update the members of the board of directors of novabay pharmaceuticals were paul e freiman xinzhou li paul li gail maderis t alex mcpherson md phd massimo radaelli phd mark sieczkarek mijia wu bob wu and xiaoyan liu henry liu productsedit products on the marketedit avenova formerly known as ilid cleanser  neutrophase  cellerx for plastic surgery products under developmentedit novabay developed a method for making a stable pure form of hypochlorous acid hocl a substance produced by the immune system as an effective first defense against microbial invaders the company calls their proprietary formulation neutrox the companys chemists also created a related family of compounds which the company calls aganocides the company is currently developing compounds with antibacterial and antiviral action potential applications include flesheating disease problems related to indwelling urinary catheters and common eye conditions compounds are also being developed for the veterinary market referencesedit  novabay avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients   treatment of acute necrotizing fasciitis using negative pressure wound therapy and adjunctive neutrophase irrigation under the foam   nnff names novabays nby neutrophase its official flesheating disease wound cleanser   hypochlorous acid as a potential wound care agent part i pdf   k summary neutrophase® skin and wound cleaner otc pdf   novabay’s new advanced ilid cleanser has been cleared by the fda for cleaning removing debris and microbes from the skin around the eyes the eyelids and eyelashes eyelid and lash cleansing as part of a regimen for blepharitis  steven e f brown february   novabay pharmaceuticals makes deal for flesheating bacteria cleanser san francisco business times retrieved june     novabay pharmaceuticals and virbac enter into a collaboration and license agreement for animal health  external linksedit companies portal wwwnovabaycom wwwavenovacom wwwdoctorsavenovacom wwwneutrophasecom wwwcellerxcom novabay pharmaceuticals inc the new york times v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitlenovabaypharmaceuticalsoldid categories companies listed on nyse mktpharmaceutical companies of the united statescompanies based in emeryville californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories articles needing additional references from june all articles needing additional referencespages using deprecated image syntaxall articles with unsourced statementsarticles with unsourced statements from june all articles with failed verificationarticles with failed verification from june articles containing potentially dated statements from april all articles containing potentially dated statements navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view novabay pharmaceuticals’ neutrox® product line receives ce mark and iso certification for the european unionhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  minssp futures dow futures nasdaq futures novabay pharmaceuticals’ neutrox® product line receives ce mark and iso certification for the european unionbusiness wireseptember  reblogsharetweetshareemeryville califbusiness wirenovabay® pharmaceuticals inc nyse mkt nby a biopharmaceutical company focusing on commercializing prescription avenova® lid and lash hygiene in the domestic eye care market announces that its neutrox® product line has received the ce mark clearing the way for this product to be sold in european union and certain other countries and iso  certification satisfying a critical step in european approval process“it’s gratifying to report that our neutrox product line which includes avenova has met the rigorous quality and safety standards to successfully complete the applications for both the ce mark and iso certification” said mark m sieczkarek novabay’s chairman president and ceo “while we are committed to accelerating sales in the largely untapped us market these authorizations provide future opportunities to expand into significant new markets either through distributors or with our own sales organization“avenova’s distinct advantages in managing chronic blepharitis are increasingly gaining recognition by eye care specialists both in the us and abroad” he added “avenova is the only eye care product based on our unique formulation of hypochlorous acid with no bleach impurities and is the only commercial eye care product proven in a multicenter clinical study to substantially reduce bacteria that can cause blepharitis”about novabay pharmaceuticals inc going beyond antibioticsnovabay pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription avenova® lid and lash hygiene for the eye care market avenova is formulated with neutrox™ which is cleared by the us food and drug administration fda as a k medical device neutrox is novabay’s pure hypochlorous acid laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is nontoxic to mammalian cells and it also neutralizes bacterial toxins data from a multicenter clinical study show that avenova reduced bacterial load the underlying cause of blepharitis on ocular skin surface by more than  avenova is marketed to optometrists and ophthalmologists throughout the us by novabay’s direct medical salesforce it is accessible from more than  of retail pharmacies in the us through agreements with mckesson corporation cardinal health and amerisource bergenforwardlooking statementsthis release contains forwardlooking statements which are based upon managements current expectations assumptions estimates projections and beliefs these statements include but are not limited to statements regarding the implied impact of obtaining the ce mark and iso certification on the company’s future financial results these statements involve known and unknown risks uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forwardlooking statements factors that might cause or contribute to such differences include but are not limited to risks and uncertainties relating to the actual quality of our products and possible difficulties or delays in manufacturing and distribution other risks relating to novabay’s business including risks that could cause results to differ materially from those projected in the forwardlooking statements in this press release are detailed in novabays latest form k and form q filings with the securities and exchange commission especially under the heading risk factors the forwardlooking statements in this release speak only as of this date and novabay disclaims any intent or obligation to revise or update publicly any forwardlooking statement except as required by lawstay informed on novabays progressdownload our mobile investorapp from the apple store or google playlike us on facebookfollow us on twitterconnect with novabay on linkedinjoin us on googlevisit novabays websiteview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nexteu court rejects opendoor policy and upholds right of member states to deport refugees the telegraphengineer finds pattern makes millions in stocksmoney morningsponsoredcan type  diabetes be reversedthe doctors tvwhy russias market is rising after sanctions bill wins approvalbloombergeu court upholds hamas terror listingafpdiscover it  out of  avg by k customersdiscover cardsponsoredwhy eu court of justice is a key brexit battlegroundbloombergkristin beck transgender navy seal hero lets meet face to face and you tell me im not worthybusiness insiderdollar steadies after fed skid shares hit new highsreutersare you still interested in a travel rewards cardwise breadsponsoredphil mickelson trashtalked jordan spieth at the open championship — and phil is going to have to eat his wordsbusiness insideramazon’s echo rivaled by xiaomi and facebook rptyahoo finance videoamazon the benevolent dictatoryahoo financewomen everywhere should carry this tiny devicesiren songsponsoredap exclusive boy scouts chief expected a fiery trump speechassociated presswhy everybody should be happy that flash is finally dyingyahoo financewhat to know about trump and the th amendmentmichael carrigan how about the congressional capacity act failure to reduce spending and pay down the debt is a mental disorderjoin the conversation    facebook facebook   ？ facebook ？？：？，。english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   nby stock price  novabay pharmaceuticals inc stock quote us nyse american  marketwatch sections watchlist signup • login search bulletin us weekly unemploymentbenefits claims rise bulletin us durablegoods orders jump in june bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers ba  t  amd  biib  akam  uhs  rhi  jnpr  latest newsall times eastern a volkswagen profit rises as emissions effect wanes a us jobless claims climb  to  a new york times sees q subscription revenue to increase in line with q rate a new york times sees q ad revenue down mid to highsingle digits percentage range a new york times q print advertising revenue down  digital ad revenue up  a new york times q subscriber revenue up  advertising revenue up  a new york times q digitalonly subscriber additions  up  from a year ago a boeing bonanza durablegoods orders soar  in june a wasserman schultz kept paying aide suspected of stealing house computers   governors slam obamacare ‘skinny repeal’ a new york times q revenue  mln vs  mln factset consensus  mln to be replaced home investing quotes stocks united states nby overview compare quotes stock screener earnings calendar sectors nby us nyse american join td ameritrade find a broker novabay pharmaceuticals inc watchlist createnbyalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones no headlines available novabay not seen breaking even for years apr   at  am et on barrons novabay pharmaceuticals inc jan   at  pm et on the wall street journal recent news other news press releases  biggest midday gainers for thursday  biggest midday gainers for thursday jun   at  am et on benzingacom  biggest midday gainers for friday  biggest midday gainers for friday jun   at  am et on benzingacom  biggest midday gainers for monday  biggest midday gainers for monday jun   at  am et on benzingacom analyst action  healthcare analyst action  healthcare jun   at  am et on seeking alpha benzingas top upgrades downgrades for june   benzingas top upgrades downgrades for june   jun   at  am et on benzingacom novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript may   at  pm et on seeking alpha premarket analyst action  healthcare mar   at  am et on seeking alpha novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript mar   at  pm et on seeking alpha novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript mar   at  pm et on seeking alpha k novabay pharmaceuticals inc mar   at  pm et on edgar online  edg  q k hottest manufacturing stocks now – mrus cala invn mntx dec   at  am et on investorplacecom  pharmaceuticals stocks to buy now dec   at  am et on investorplacecom biggest movers in manufacturing stocks now – strt rprx reta supn nov   at  am et on investorplacecom biggest movers in manufacturing stocks now – crbp crds ebio mtl nov   at  am et on investorplacecom hottest manufacturing stocks now – dmtx cxrx fate vtl nov   at  pm et on investorplacecom novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript nov   at  pm et on seeking alpha novabay regains compliance with nyse continued listing requirements oct   at  am et on seeking alpha  pharmaceuticals stocks to buy now oct   at  am et on investorplacecom  pharmaceuticals stocks to buy now oct   at  am et on investorplacecom biggest movers in manufacturing stocks now – crbp chma crmd nby oct   at  am et on investorplacecom fighting parasitic eyelid mites with avenova from novabay pharmaceuticals fighting parasitic eyelid mites with avenova from novabay pharmaceuticals jul   at  am et on accesswire update novabays avenova highlighted in national dry eye awareness month update novabays avenova highlighted in national dry eye awareness month jul   at  pm et on accesswire novabays avenova highlighted in national dry eye awareness month novabays avenova highlighted in national dry eye awareness month jul   at  am et on accesswire novabay pharmaceuticals announces cfo transition novabay pharmaceuticals announces cfo transition jul   at  am et on businesswire  bzx novabay pharmaceuticals joins the russell microcap index novabay pharmaceuticals joins the russell microcap index jun   at  am et on businesswire  bzx novabay pharmaceuticals to present at the th annual ld micro invitational novabay pharmaceuticals to present at the th annual ld micro invitational may   at  am et on businesswire  bzx novabay pharmaceuticals receives noncompliance notice from nyse mkt novabay pharmaceuticals receives noncompliance notice from nyse mkt may   at  pm et on businesswire  bzx novabay pharmaceuticals reports first quarter  financial results novabay pharmaceuticals reports first quarter  financial results may   at  pm et on businesswire  bzx novabay pharmaceuticals to hold  first quarter conference call on may   novabay pharmaceuticals to hold  first quarter conference call on may   may   at  am et on businesswire  bzx avenova from novabay pharmaceuticals is effective for managing dry eye before refractive and cataract eye surgery avenova from novabay pharmaceuticals is effective for managing dry eye before refractive and cataract eye surgery may   at  am et on accesswire novabays intellicase can safely and effectively disinfect contact lenses ceocfo magazine reports apr   at  am et on accesswire avenova from novabay pharmaceuticals effective for painful eye condition mar   at  am et on accesswire novabay pharmaceuticals to hold  fourth quarter and full year conference call on march   mar   at  am et on businesswire  bzx novabay pharmaceuticals to present features and benefits of the intellicase at fda public advisory meeting mar   at  am et on businesswire  bzx explaining innovative drug technologies through animation mar   at  am et on accesswire novabay pharmaceuticals to present at th annual roth conference mar   at  am et on businesswire  bzx relief from painful dry eye can be a real valentines day gift feb   at  am et on accesswire novabay ceo sees continued doubledigit revenue growth in  jan   at  am et on accesswire novabay pharmaceuticals avenova helping patients with contact lens intolerance jan   at  am et on accesswire novabays avenova brings quick relief to children suffering from eye conditions writes steven j lichtenstein md dec   at  am et on marketwired novabay pharmaceuticals inc novabay pharmaceuticals inc is a biopharmaceutical company it engages in developing products for the eye care the companys products include avenova which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to blepharitis meibomian gland dysfunction and dry eye neutrophase is a skin and wound cleanser consisting of neutrox and cellerx it cleans calms and soothes skins novabay pharmaceuticals was founded by ramin najafi on january   and is headquartered in emeryville ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top upgrades downgrades for june   jun   at  am et on benzingacom maxim rates novabay at buy says the eyes have it apr   at  am et on benzingacom competitors name chg  market cap johnson  johnson  b cempra inc  m tetraphase pharmaceuticals inc  m oragenics inc  m nanoviricides inc  m competitor data provided by partner content trending tickers powered by fb  twtr  clf  amzn  snap  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin us weekly unemploymentbenefits claims rise » us durablegoods orders jump in june » investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest avolkswagen profit rises as emissions effect wanes aus jobless claims climb  to  anew york times sees q subscription revenue to increase in line with q rate anew york times sees q ad revenue down mid to highsingle digits percentage range anew york times q print advertising revenue down  digital ad revenue up  anew york times q subscriber revenue up  advertising revenue up  anew york times q digitalonly subscriber additions  up  from a year ago aboeing bonanza durablegoods orders soar  in june anew york times q revenue  mln vs  mln factset consensus  mln awasserman schultz kept paying aide suspected of stealing house computers   governors slam obamacare ‘skinny repeal’ anew york times q adj eps  cents factset consensus  cents aaugust gold rises  at oz anew york times q eps  cents vs breakeven a year ago agold adds to sharp early gain after reports on joblessclaims durablegoods trade apinnacle foods shares fall after sales miss aus dollar unchanged after durablegoods jobless claims aeuro at  dollar at ¥ aice dollar index unchanged at  atreasury yields tick higher after durable goods jobless claims aus stockindex futures hold gains after jobless claims data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin us weekly unemploymentbenefits claims rise » us durablegoods orders jump in june » investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest avolkswagen profit rises as emissions effect wanes aus jobless claims climb  to  anew york times sees q subscription revenue to increase in line with q rate anew york times sees q ad revenue down mid to highsingle digits percentage range anew york times q print advertising revenue down  digital ad revenue up  anew york times q subscriber revenue up  advertising revenue up  anew york times q digitalonly subscriber additions  up  from a year ago aboeing bonanza durablegoods orders soar  in june anew york times q revenue  mln vs  mln factset consensus  mln awasserman schultz kept paying aide suspected of stealing house computers   governors slam obamacare ‘skinny repeal’ anew york times q adj eps  cents factset consensus  cents aaugust gold rises  at oz anew york times q eps  cents vs breakeven a year ago agold adds to sharp early gain after reports on joblessclaims durablegoods trade apinnacle foods shares fall after sales miss aus dollar unchanged after durablegoods jobless claims aeuro at  dollar at ¥ aice dollar index unchanged at  atreasury yields tick higher after durable goods jobless claims aus stockindex futures hold gains after jobless claims data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin us weekly unemploymentbenefits claims rise » us durablegoods orders jump in june » investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest avolkswagen profit rises as emissions effect wanes aus jobless claims climb  to  anew york times sees q subscription revenue to increase in line with q rate anew york times sees q ad revenue down mid to highsingle digits percentage range anew york times q print advertising revenue down  digital ad revenue up  anew york times q subscriber revenue up  advertising revenue up  anew york times q digitalonly subscriber additions  up  from a year ago aboeing bonanza durablegoods orders soar  in june anew york times q revenue  mln vs  mln factset consensus  mln awasserman schultz kept paying aide suspected of stealing house computers   governors slam obamacare ‘skinny repeal’ anew york times q adj eps  cents factset consensus  cents aaugust gold rises  at oz anew york times q eps  cents vs breakeven a year ago agold adds to sharp early gain after reports on joblessclaims durablegoods trade apinnacle foods shares fall after sales miss aus dollar unchanged after durablegoods jobless claims aeuro at  dollar at ¥ aice dollar index unchanged at  atreasury yields tick higher after durable goods jobless claims aus stockindex futures hold gains after jobless claims data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  nby stock price  novabay pharmaceuticals inc stock quote us nyse american  marketwatch sections watchlist signup • login search bulletin us weekly unemploymentbenefits claims rise bulletin us durablegoods orders jump in june bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers ba  t  amd  biib  akam  uhs  rhi  jnpr  latest newsall times eastern a volkswagen profit rises as emissions effect wanes a us jobless claims climb  to  a new york times sees q subscription revenue to increase in line with q rate a new york times sees q ad revenue down mid to highsingle digits percentage range a new york times q print advertising revenue down  digital ad revenue up  a new york times q subscriber revenue up  advertising revenue up  a new york times q digitalonly subscriber additions  up  from a year ago a boeing bonanza durablegoods orders soar  in june a wasserman schultz kept paying aide suspected of stealing house computers   governors slam obamacare ‘skinny repeal’ a new york times q revenue  mln vs  mln factset consensus  mln to be replaced home investing quotes stocks united states nby overview compare quotes stock screener earnings calendar sectors nby us nyse american join td ameritrade find a broker novabay pharmaceuticals inc watchlist createnbyalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones no headlines available novabay not seen breaking even for years apr   at  am et on barrons novabay pharmaceuticals inc jan   at  pm et on the wall street journal recent news other news press releases  biggest midday gainers for thursday  biggest midday gainers for thursday jun   at  am et on benzingacom  biggest midday gainers for friday  biggest midday gainers for friday jun   at  am et on benzingacom  biggest midday gainers for monday  biggest midday gainers for monday jun   at  am et on benzingacom analyst action  healthcare analyst action  healthcare jun   at  am et on seeking alpha benzingas top upgrades downgrades for june   benzingas top upgrades downgrades for june   jun   at  am et on benzingacom novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript may   at  pm et on seeking alpha premarket analyst action  healthcare mar   at  am et on seeking alpha novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript mar   at  pm et on seeking alpha novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript mar   at  pm et on seeking alpha k novabay pharmaceuticals inc mar   at  pm et on edgar online  edg  q k hottest manufacturing stocks now – mrus cala invn mntx dec   at  am et on investorplacecom  pharmaceuticals stocks to buy now dec   at  am et on investorplacecom biggest movers in manufacturing stocks now – strt rprx reta supn nov   at  am et on investorplacecom biggest movers in manufacturing stocks now – crbp crds ebio mtl nov   at  am et on investorplacecom hottest manufacturing stocks now – dmtx cxrx fate vtl nov   at  pm et on investorplacecom novabay pharmaceuticals nby ceo mark sieczkarek on q  results  earnings call transcript nov   at  pm et on seeking alpha novabay regains compliance with nyse continued listing requirements oct   at  am et on seeking alpha  pharmaceuticals stocks to buy now oct   at  am et on investorplacecom  pharmaceuticals stocks to buy now oct   at  am et on investorplacecom biggest movers in manufacturing stocks now – crbp chma crmd nby oct   at  am et on investorplacecom fighting parasitic eyelid mites with avenova from novabay pharmaceuticals fighting parasitic eyelid mites with avenova from novabay pharmaceuticals jul   at  am et on accesswire update novabays avenova highlighted in national dry eye awareness month update novabays avenova highlighted in national dry eye awareness month jul   at  pm et on accesswire novabays avenova highlighted in national dry eye awareness month novabays avenova highlighted in national dry eye awareness month jul   at  am et on accesswire novabay pharmaceuticals announces cfo transition novabay pharmaceuticals announces cfo transition jul   at  am et on businesswire  bzx novabay pharmaceuticals joins the russell microcap index novabay pharmaceuticals joins the russell microcap index jun   at  am et on businesswire  bzx novabay pharmaceuticals to present at the th annual ld micro invitational novabay pharmaceuticals to present at the th annual ld micro invitational may   at  am et on businesswire  bzx novabay pharmaceuticals receives noncompliance notice from nyse mkt novabay pharmaceuticals receives noncompliance notice from nyse mkt may   at  pm et on businesswire  bzx novabay pharmaceuticals reports first quarter  financial results novabay pharmaceuticals reports first quarter  financial results may   at  pm et on businesswire  bzx novabay pharmaceuticals to hold  first quarter conference call on may   novabay pharmaceuticals to hold  first quarter conference call on may   may   at  am et on businesswire  bzx avenova from novabay pharmaceuticals is effective for managing dry eye before refractive and cataract eye surgery avenova from novabay pharmaceuticals is effective for managing dry eye before refractive and cataract eye surgery may   at  am et on accesswire novabays intellicase can safely and effectively disinfect contact lenses ceocfo magazine reports apr   at  am et on accesswire avenova from novabay pharmaceuticals effective for painful eye condition mar   at  am et on accesswire novabay pharmaceuticals to hold  fourth quarter and full year conference call on march   mar   at  am et on businesswire  bzx novabay pharmaceuticals to present features and benefits of the intellicase at fda public advisory meeting mar   at  am et on businesswire  bzx explaining innovative drug technologies through animation mar   at  am et on accesswire novabay pharmaceuticals to present at th annual roth conference mar   at  am et on businesswire  bzx relief from painful dry eye can be a real valentines day gift feb   at  am et on accesswire novabay ceo sees continued doubledigit revenue growth in  jan   at  am et on accesswire novabay pharmaceuticals avenova helping patients with contact lens intolerance jan   at  am et on accesswire novabays avenova brings quick relief to children suffering from eye conditions writes steven j lichtenstein md dec   at  am et on marketwired novabay pharmaceuticals inc novabay pharmaceuticals inc is a biopharmaceutical company it engages in developing products for the eye care the companys products include avenova which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to blepharitis meibomian gland dysfunction and dry eye neutrophase is a skin and wound cleanser consisting of neutrox and cellerx it cleans calms and soothes skins novabay pharmaceuticals was founded by ramin najafi on january   and is headquartered in emeryville ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top upgrades downgrades for june   jun   at  am et on benzingacom maxim rates novabay at buy says the eyes have it apr   at  am et on benzingacom competitors name chg  market cap johnson  johnson  b cempra inc  m tetraphase pharmaceuticals inc  m oragenics inc  m nanoviricides inc  m competitor data provided by partner content trending tickers powered by fb  twtr  clf  amzn  snap  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience novabay pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of novabay pharmaceuticals inc snapshot people company overview novabay pharmaceuticals inc a pharmaceutical company develops manufactures and markets antiinfective products for the eye care market in the united states its commercial products include the neutrox family of products avenova for the eye care market aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria viruses and fungi auriclosene irrigation solution for urology cellerx for the dermatology market intellicase a device for soft and rigid gas permeable contact lenses and neutrophase for wound care the company has collaboration and license agreement with virbac to develop its auriclosene compounds for veterinary markets the compan novabay pharmaceuticals inc a pharmaceutical company develops manufactures and markets antiinfective products for the eye care market in the united states its commercial products include the neutrox family of products avenova for the eye care market aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria viruses and fungi auriclosene irrigation solution for urology cellerx for the dermatology market intellicase a device for soft and rigid gas permeable contact lenses and neutrophase for wound care the company has collaboration and license agreement with virbac to develop its auriclosene compounds for veterinary markets the company was formerly known as novacal pharmaceuticals inc and changed its name to novabay pharmaceuticals inc in february  novabay pharmaceuticals inc was incorporated in  and is based in emeryville california detailed description  powell streetsuite emeryville ca united statesfounded in  employees phone  fax  wwwnovabaypharmacom key executives for novabay pharmaceuticals inc mr mark m sieczkarek mba chairman chief executive officer and president age  total annual compensation k mr justin m hall esq senior vice president and general counsel age  total annual compensation k mr thomas j paulson mba executive age  total annual compensation k compensation as of fiscal year  novabay pharmaceuticals inc key developments novabay pharmaceuticals inc announces management changes jul   novabay pharmaceuticals inc announced that jack mcgovern will join the company as chief financial officer as of july   current cfo thomas tom paulson a year healthcare finance veteran will continue with the company through his retirement at the end of the year and will lead it’s annual strategic planning process oversee investor relations activities and ensure a smooth transition to mr mcgovern mr mcgovern has more than  years of experience in finance and operations primarily in the san francisco bay area since  he was chief operating officer and cfo of attainia inc previously for eight years he was managing partner at northshore management partners earlier he was coocfo at integrated biosystems executive vice president at strategic capital inc novabay pharmaceuticals not in compliance with nyse listing standards may   on may   novabay pharmaceuticals inc was notified by the nyse mkt that the company is not in compliance with section aiii of the nyse mkt company guide requiring stockholders’ equity of  million or more if it has reported losses from continuing operations andor net losses in its five most recent fiscal years therefore the company has become subject to the procedures and requirements of section  of the nyse mkt company guide and must submit a plan of compliance by june   addressing how it intends to regain compliance with section aiii of the nyse mkt company guide as of march   the company had stockholders’ equity of  million the company intends to submit a plan to regain compliance with nyse mkt listing standards if the company does not regain compliance with those standards or does not make progress consistent with the plan the nyse mkt staff may commence delisting proceedings the company’s common stock will continue to be listed on the nyse mkt during the plan period novabay pharmaceuticals inc presents at th annual ld micro invitational jun  pm may   novabay pharmaceuticals inc presents at th annual ld micro invitational jun  pm venue luxe sunset boulevard hotel los angeles california united states similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact novabay pharmaceuticals inc please visit wwwnovabaypharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close nby key statistics  novabay pharmaceuticals inc financial ratios  marketwatch bulletin us weekly unemploymentbenefits claims rise » us durablegoods orders jump in june » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close novabay pharmaceuticals inc nyse american nby go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus novabay pharmaceuticals inc market closed  quotes are delayed by  min jul    pm nby quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description novabay pharmaceuticals inc is a biopharmaceutical company it engages in developing products for the eye care the companys products include avenova which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to blep novabay pharmaceuticals inc is a biopharmaceutical company it engages in developing products for the eye care the companys products include avenova which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to blepharitis meibomian gland dysfunction and dry eye neutrophase is a skin and wound cleanser consisting of neutrox and cellerx it cleans calms and soothes skins novabay pharmaceuticals was founded by ramin najafi on january   and is headquartered in emeryville ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr mark m sieczkarek   chairman president  chief executive officer mr jack j mcgovern   chief financial officer dr yonghao ma   director mr todd erik zavodnick   director mr xiaoyan liu   nonindependent director insider actions – purchase – sale  – number of transactions  locok loccancel its christmas in july take  off your qualified purchase  get free shipping shop sale     shop sale     its christmas in july take  off yourqualified purchase  get free shipping shop sale       toll free  shopping cart   like us   nutritional supplements all products quality about us contact us   my account about advanced bionutritionals ®about advanced bionutritionals ® advanced bionutritionals is a cutting edge line of nutraceuticals we work closely with our suppliers and our manufacturers to ensure that your supplements are made with fresh quality ingredients following good manufacturing practice guidelines our highly qualified team is always researching new and better ingredients to ensure safe effective health solutions for you frank shallenberger md dr shallenberger has practiced medicine for more than  years after earning his md degree from the university of maryland school of medicine and receiving postgraduate training at mt zion hospital in san francisco dr shallenberger is also certified by the american board of antiaging medicine abaam as an antiaging physician and has also been trained and certified in other areas of alternative medicine this makes dr shallenberger one of a small minority of doctors in this country licensed in conventional as well as alternative medicine but more importantly it allows him to integrate the best of both approaches for optimal results at his wellness clinic the nevada center of alternative and antiaging medicine dr shallenberger has been on the forefront of integrative medicine for several years with his involvement with the american college for the advancement of medicine acam the american preventive medical association and the american academy of antiaging medicine he currently serves as an officer for the orthomolecular medicinehealth society omh founded in honor of twotime nobel prize winner linus pauling dr shallenberger has trained hundreds of physicians on his innovative medical treatments and published numerous scientific papers he is a past clinical instructor of family medicine at the university of californiadavis school of medicine he is also the author of two health books bursting with energy and the type  diabetes breakthrough dr shallenberger also writes the monthly newsletter second opinion shop dr shallenbergers products janet zand omd lac dr janet zand omd lac is a board certified acupuncturist a doctor of oriental medicine a nationally respected author lecturer natural health practitioner and herbal and nutraceutical products formulator who has helped thousands of people achieve better health in magazine describes dr zand as hollywoods best kept health secret because of her alist clientele of movie stars rock stars and professional athletes with over  years of experience in natural medicine she was the cofounder of mczand herbal and the formulator of zand herbal formulas which are sold in natural health stores throughout the country dr zand is also the coauthor of three books on natural health and healing including smart medicine for a healthier child smart medicine for healthier living and the nitric oxide solution she has been featured in elle allure the los angeles times life time tv and the bbc she is the lead formulator for the systeme ® line of allnatural skin care products and edits the popular skin care insider weekly for information about skin care insider visit the website at httpwwwsystemecom she is the editor in chief of womens health letter where each month she brings her readers ways to help them improve their health enjoy their life and thrive shop dr zands supplements steve kroening nd for over  years steve kroening has worked handinhand with some of the nations top doctors including drs frank shallenberger janet zand nan kathryn fuchs william campbell douglass and bestselling author james balch steve is the author of the book practical guide to home remedies as a health journalist steves articles have appeared in countless magazines blogs and websites steve researches breakthrough cures and treatments you wont hear about from mainstream medicine or even other alternative writers he writes in a friendly easytoread style that always gives you the power to guide your own health choices and do more research on your own shop dr kroenings supplements isaac eliaz md ms lac a native of israel dr eliaz received his medical degree from tel aviv university dr eliaz pursued graduate studies in clinical herbology at hebrew university of jerusalem and classical chinese medicine with teachers in israel and europe in  dr eliaz moved to the san francisco bay area in order to continue his studies at the american college of traditional chinese medicine earning a master of science degree in  he currently operates a busy private practice in northern california focusing primarily on integrative holistic protocols as an innovative formulator of dietary supplements dr eliaz developed and currently holds the patents for several of his unique herbal formulations some of these products are available through advanced bionutritionals shop our nutritional supplements free ebook sign up today for free to nutrient insider and be the first to get the latest nutrient breakthroughs you’ll also get immediate access to our ebook “how to make your supplements work even better” submit × free report sign up today for free to nutrient insider and be the first to get the latest nutrient breakthroughs youll also get immediate access to our ebook how to make your supplements work even better advanced bionutritionals® products are manufactured in the usa from globally sourced ingredients by formulation technology inc novabay pharmaceuticals inc novabay pharmaceuticals inc no menu assigned           presenting a sea change in lid  lash hygiene avenova® is formulated with neutrox® novabay’s pure proprietary hypochlorous acid formulation go beyond betadine with avenova learn more about avenova novabay is a biopharmaceutical company focusing on the commercialization of prescription avenova® for the eye care market about us avenova is the essential part of any lid and lash hygiene regimen learn about our products novabay is addressing the large unmet therapeutic needs of the global antiinfective market with its pure proprietary stable form of hypochlorous acid called neutrox® information for investors top about management team board of directors ophthalmic advisory board optometry advisory board contact us technology neutrox aganocides products avenova neutrophase cellerx partners iht pioneer pharma principle business enterprises virbac investors events corporate governance corporate presentation composition of board committees sec filings stock information news press releases published articles posters media copyright   novabay pharmaceuticals inc all rights reserved legal disclaimer about about management team board of directors ophthalmic advisory board optometry advisory board technology technology neutrox aganocides products products avenova neutrophase cellerx partners partners iht pioneer pharma principle business enterprises virbac investors investors events corporate governance corporate presentation composition of board committees sec filings stock information news news press releases published articles posters media contact we’re hiring bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one